This enabled us to demonstrate that the noninvasive measurement of metabolic reprogramming associated IDH mutant brain tumors via in vivo MRS holds excellent value for a molecule-specific, clinically relevant, personalized biomarker. The gene discussed is IDH2; the disease is brain neoplasm.